NovaBridge Biosciences

Well-capitalized clinical-stage oncology company with materially de-risking Phase 1b/2 data and an FDA accelerated-approval pathway for its lead bispecific.

Strengths

• $211M cash (69th pct) and current ratio ~8x (76th pct) fund the pipeline well
• Givastomig Phase 1b ORR ~77% with 16.9-mo median PFS; FDA aligned on accelerated approval, registrational Phase 3 planned Q4 2026

Risks

• Still pre-revenue with negative ROE (-20%) and ROA (-18%); net loss widened to $88M
• Identified material weakness in IT controls and residual China/PRC exposure

Notable findings

• High convictionHigh conviction — notable institutional holders, insider buying, and a strong balance sheet
• Material weakness• We have identified material weaknesses in our internal control related to ineffective information technology general controls which could, if not remediated, result in material misstatements in our
• Strong balance sheetStrong balance sheet — $211M cash & investments
• Insider buyingInsider buying — 1 open-market buy(s) by 1 insider(s) (~$577,300, last 6mo) Form 4 ↗
• New fund positionNotable fund(s) opened this quarter: RENAISSANCE TECHNOLOGIES LLC
• Notable holderHeld by 4 notable fund(s): STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC +1 more (as of 2026-03-31)
• Insider sellingInsider selling — 3 open-market sale(s) by 3 insider(s) (cluster of 3 insiders, last 6mo) Form 4 ↗
• AccumulatingInstitutional holders rose 5→6 QoQ (2025-12-31→2026-03-31)